Drug
Toripalimab clinical trials
Also written JS001, Tuoyi, Loqtorzi and TAB001.
- studies test it
- 364
- open now
- 190
- in phase 3
- 36
- first study started
- 2016
Keep track of what changes. Save the toripalimab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- Toripalimab
- 227
Other names
Studies by the year they started
363 studies that test it; most in 2020 (56); 1 more planned to start later
| Year | Studies |
|---|---|
| 2016 | 2 |
| 2017 | 3 |
| 2018 | 8 |
| 2019 | 43 |
| 2020 | 56 |
| 2021 | 43 |
| 2022 | 41 |
| 2023 | 39 |
| 2024 | 45 |
| 2025 | 42 |
| 2026 | 41 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 1
- Phase 1
- 81
- Phase 2
- 284
- Phase 3
- 36
- Phase 4
- 1
- No phase
- 10
What it is tested for
Each study’s main condition, where its own words name it.
- Melanoma
- 14
Who runs them
Industry 49 · Other 315
Sun Yat-sen University (47) · Shanghai Junshi Bioscience Co., Ltd. (24) · Fudan University (18) · Tianjin Medical University Cancer Institute and Hospital (13) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (8) · Peking University Cancer Hospital & Institute (8) · Peking University (7) · Shanghai Pulmonary Hospital, Shanghai, China (7)
Often tested with
Tested in the same studies.
Paclitaxel (20) · Cisplatin (15) · Anlotinib (15) · Axitinib (14) · Gemcitabine (13) · Albumin-Bound Paclitaxel (13) · Carboplatin (12) · Lenvatinib (11)
Studies
Open first, then newest update. How each study uses toripalimab is read from its arms, and is right about nine times in ten.
Testing it · 364
- Antibody-Drug Conjugate Plus Immunotherapy Versus Immunotherapy Plus Chemotherapy for Extensive Transurethrally Unresectable Very-High-Risk Non-Muscle-Invasive Bladder CancerNot yet recruitingPhase 2Tianjin Medical University Second HospitalNCT07879469Written as Disitamab Vedotin and Toripalimab
- Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter StudyRecruitingPhase 3Tianjin Medical University Cancer Institute and HospitalNCT07246330Written as Toripalimab
- A Trial of LBL-024 Monotherapy or Combination With Toripalimab in Patients With Advanced Melanoma.RecruitingPhase 1/2Nanjing Leads Biolabs Co.,LtdNCT07099430Written as Toripalimab Injection
- Propranolol Hydrochloride Combined With Toripalimab and Platinum-based Chemotherapy in Resectable Non-Small Cell Lung CancerRecruitingPhase 1Second Xiangya Hospital of Central South UniversityNCT07886229Written as Toripalimab
- Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin Therapy in Local Advanced Bladder Cancer SubjectsRecruitingPhase 2Zhujiang HospitalNCT04861584Written as Neoadjuvant Toripalimab in Combination With Gemcitabine and Cisplatin
- Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon CancerRecruitingPhase 2Emory UniversityNCT07140679Written as Toripalimab
- Multicenter, Single-Arm, Prospective Phase II Study of Neoadjuvant Cryo-Thermal Ablation Combined With Toripalimab and Chemotherapy for Resectable Stage IB-IIIB Non-Small Cell Lung CancerRecruitingPhase 2West China HospitalNCT07855965Written as Toripalimab
- DV Plus Toripalimab With Cetirizine and Mecobalamin Pretreatment in Patients With Locally Advanced Unresectable or Metastatic Bladder CancerNot yet recruitingPhase 1Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07853053Written as Toripalimab
- PhII Study of Toripalimab Followed by Definitive CRT & Adjuvant Toripalimab in Locally Advanced ESCCNot yet recruitingPhase 2Vanderbilt-Ingram Cancer CenterNCT07836049Written as Toripalimab
- Phase Ⅰ/Ⅱ Clinical Study to Evaluate ABO2011 in Advanced Solid TumorsRecruitingPhase 1/2Suzhou Abogen Biosciences Co., Ltd.NCT06088004Written as Toripalimab
- Rimegepant Plus Toripalimab in Advanced Urothelial Carcinoma After Failure of Standard TherapyRecruitingPhase 1Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07835035Written as Toripalimab
- Neoadjuvant Sacituzumab Tirumotecan Plus Toripalimab in Locally Advanced Esophageal Squamous Cell CarcinomaNot yet recruitingPhase 2Hebei Medical University Fourth HospitalNCT07823270Written as Toripalimab
- Toripalimab Plus Sacituzumab Tirumotecan as Neoadjuvant Therapy for Resectable NSCLCNot yet recruitingPhase 2Shaodong HongNCT07819578Written as Toripalimab
- MANTIS-RCC: Toripalimab-Axitinib Induction in TLS-Positive Advanced Non-Clear Cell and Renal Medullary CarcinomasNot yet recruitingPhase 2Fudan UniversityNCT07816770Written as Toripalimab
- SBRT Combined With Reduced-Dose Anthracycline Chemotherapy and Toripalimab as Neoadjuvant Therapy for Localized High-Risk Undifferentiated Pleomorphic SarcomaNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07817095Written as Toripalimab
- Toripalimab Combined With Intravesical Gemcitabine as Adjuvant Therapy for High-Risk Non-Muscle-Invasive Bladder Cancer After TURBTNot yet recruitingPhase 2Tianjin First Central HospitalNCT07808216Written as Toripalimab (JS001 )
- Sequential Toripalimab and Paclitaxel in Patients With Head and Neck Squamous Cell Cancer (HNSCC) and Poor Performance StatusNot yet recruitingPhase 2Barbara Ann Karmanos Cancer InstituteNCT07796126Written as Toripalimab
- Toripalimab With Chemotherapy for Sinus CancerRecruitingPhase 2Dana-Farber Cancer InstituteNCT06940180Written as Toripalimab
- TACTIC-RCC: Toripalimab Plus Axitinib Induction With Selective Deferred Cytoreductive Nephrectomy in TLS-Positive Advanced Clear Cell Renal Cell CarcinomaNot yet recruitingPhase 2Fudan UniversityNCT07776717Written as Toripalimab
- Neoadjuvant SBRT Followed by Nab-Paclitaxel Combined With Toripalimab in HR+/HER2- Breast CancerRecruitingPhase 2Xijing HospitalNCT06914440Written as Toripalimab
See all 364 studies that test toripalimab →
Given in every arm · 81 — toripalimab is usual care beside what is tested
- A LM-302 Combination With Other Anti-Tumor Therapies Phase ll StudyRecruitingPhase 2LaNova Medicines Zhejiang Co., Ltd.NCT05934331Written as Toripalimab
- PDT For Induction Therapy For Head And Neck CancerRecruitingPhase 2Massachusetts General HospitalNCT07214987Written as Toripalimab-tpzi
- Window of Opportunity in Preserving Laryngeal Function TrialRecruitingPhase 2Matthew SpectorNCT07423078Written as Toripalimab
- A Study of DXC006 With Immune Checkpoint Inhibitors or Platinum for Small Cell Lung Cancer.RecruitingPhase 1/2Hangzhou DAC Biotechnology Co., Ltd.NCT07559929Written as Toripalimab
- Au-TMP and Radiotherapy for Advanced Melanoma With Anti-PD-1 TherapyRecruitingPhase 1West China HospitalNCT07562841Written as Toripalimab
- A Single-arm, Multicenter Clinical Study of Iparomlimab and Toripalimab in Combination With Bevacizumab and Chemotherapy as First-line Treatment for Advanced Biliary Tract CancerRecruitingPhase 4Xianglin YuanNCT07619235Written as Iparomlimab and Toripalimab
- Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 StudyNot yet recruitingPhase 2First Affiliated Hospital of Wenzhou Medical UniversityNCT07189793Written as Toripalimab
- A Phase I/II Study of LM-2417 in Subjects With Advanced Solid TumoursRecruitingPhase 1/2LaNova Medicines LimitedNCT06682780Written as Toripalimab/Tirelizumab
- Bladder-Sparing Treatment With Disitamab Vedotin and Toripalimab With or Without Pelvic Lymph Node Dissection in Bladder CancerNot yet recruitingPhase 2/3Tianjin Medical University Second HospitalNCT07756008Written as Toripalimab
- MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell CarcinomaNot yet recruitingPhase 2Dongguan People's HospitalNCT07677475Written as Toripalimab
- Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacokinetics, and Preliminary Efficacy of FS-8002RecruitingPhase 1Shanghai Pushi Medical Science Co. LtdNCT06832982Written as Toripalimab Injection
- An Exploratory Study of Personalized Cancer Vaccine in Adjuvant Therapy of Solid TumorsRecruitingEarly Phase 1Ruijin HospitalNCT07680582Written as Toripalimab
- Surgery vs. Radical Chemoradiotherapy for Esophageal SCC After Neoadjuvant ImmunochemotherapyRecruitingPhase 3Henan Cancer HospitalNCT07629817Written as Toripalimab + Nab-paclitaxel + Platinum-based Chemotherapy
- Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder CancerRecruitingPhase 2Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityNCT07717242Written as Toripalimab
- A Study of CHS-114 (Tagmokitug) in Combination With Toripalimab and/or Other Treatments in Participants With Advanced Solid TumorsRecruitingPhase 1Coherus Oncology, Inc.NCT06657144Written as Toripalimab
- Toripalimab Combined With Platinum-based Chemotherapy With or Without H1 Receptor Antagonist in the Perioperative Treatment of Resectable Non-small Cell Lung CancerNot yet recruitingPhase 2Tianjin Medical University Cancer Institute and HospitalNCT07358689Written as Toripalimab (240mg day1, Q3W*3cycle)
- PTC-Guided Atorvastatin Plus Axitinib and Toripalimab in Advanced RCCNot yet recruitingPhase 1/2Cancer Institute and Hospital, Chinese Academy of Medical SciencesNCT07630363Written as Toripalimab
- Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid TumorsRecruitingPhase 2Shanghai Junshi Bioscience Co., Ltd.NCT07480733Written as Toripalimab
- HOPE-07-MIBC: Disitamab Vedotin Plus Immunotherapy vs Chemoimmunotherapy in Resectable HER2-Expressing MIBCNot yet recruitingPhase 2/3West China HospitalNCT07608224Written as Toripalimab (JS001 )
- A Phase II Clinical Study Evaluating the Combination Therapy of JS212 in Patients With Advanced Lung CancerRecruitingPhase 2Shanghai Junshi Bioscience Co., Ltd.NCT07309276Written as Toripalimab
Showing 20 of 81.
As the comparator · 6 — what is tested is compared with toripalimab
- JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver CancerNot yet recruitingPhase 3Shanghai Junshi Bioscience Co., Ltd.NCT07823348Written as Toripalimab
- Neoadjuvant RC48 Plus Gemcitabine in HER2-Expressing MIBCRecruitingPhase 3Zhiquan HuNCT07693959Written as Toripalimab
- A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast CancerRecruitingPhase 1/2Nanjing Leads Biolabs Co.,LtdNCT07281976Written as Toripalimab Injection
- A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast CancerRecruitingPhase 3Suzhou Suncadia Biopharmaceuticals Co., Ltd.NCT07111832Written as Toripalimab Injection
- Efficacy and Safety Study of Disitamab Vedotin + RC148 vs. Albumin-Paclitaxone ± Toripalimab in HR-/HER2-low Breast CancerRecruitingPhase 2RemeGen Co., Ltd.NCT06642545Written as Toripalimab
- Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell CarcinomaStatus unknownPhase 2Henan Cancer HospitalNCT04229849Written as Toripalimab
Codes
What other systems call toripalimab · ClinicalTrials.gg INT001244
- MeSH (NLM) C000656314toripalimabConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) 8JXN261VVATORIPALIMABConfirmed FDA, NLM
- NCI Thesaurus C131334ToripalimabOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000656314 | toripalimab | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | 8JXN261VVA | TORIPALIMAB | Confirmed FDA, NLM |
| NCI Thesaurus | C131334 | Toripalimab | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.